

Dr. Herbert Stadler, Managing Director, Vorstand

Over the last two decades, Herbert Stadler has built a track record as one of Germany's most active biotech entrepreneurs. He has founded or co-founded several companies including Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH and DeveloGen AG. Herbert Stadler is a neurochemist by training. He obtained his Ph.D. at the Freie University of Berlin, obtained his postdoctoral lecture qualification ("Habilitation") at the University of Göttingen and headed the Molecular Neurobiology Group at the Max-Planck Institute of Biophysical Chemistry in Göttingen. He currently serves on the supervisory boards of DeveloGen AG and IBA GmbH.

Dr. Luc St-Onge, Vice President, Patents & Licenses

Dr. St-Onge has strong credentials in the biotech industry and scientific community. He obtained his Ph.D. at the University of Sherbrooke in Canada where he worked in the field of cancer. He received the Gold Medal Award for scholastic achievements from the Governor General of Canada for his studies. In 1993, he moved to Germany and was a research scientist in the laboratory of Professor Peter Gruss at the Max-Planck Institute of Biophysical Chemistry. During this time, he studied the molecular and genetic mechanisms regulating pancreas development. He joined DeveloGen AG upon its foundation where he was director of the diabetes program. Throughout his career, he has published in top ranking journals and was granted several patents related to stem cells and novel therapeutic strategies against diabetes. During his research career, Luc St-Onge received funding from the European Molecular Biology Organisation, the National Cancer Institute of Canada, the Max-Planck Society, the Bundesministerium für Bildung und Forschung (BMBF) and the European Union.

Dr. Inge Sillaber, Director, Behavioural Pharmacology

Dr. Sillaber has a comprehensive background in behavioural pharmacology with a multifaceted experience in neuroscience. Before joining Affectis, she headed the Behavioural Pharmacology Group at the Max-Planck Institute of Psychiatry. She focused on understanding the interaction of genes and environment leading to a final risk for developing psychiatric diseases like depression or abuse of psychoactive compounds. Inge Sillaber is a biologist by training and obtained her PhD in the Department of Addiction Research at the Max-Planck Institute of Psychiatry. Subsequently, she was a guest scientist at the INSERM in Bordeaux. She has published in major scientific journals, including Science and Nature, and was awarded the Sir-Hans-Krebs Prize in 2003 for her work in the field of drug addiction.

Dr. Marcelo Paez-Pereda, Director, Gene Discovery and Validation

Before joining Affectis, Dr. Paez-Pereda was leader of the Neurosignaling Group at the Max-Planck Institute of Psychiatry where he was in charge of several drug discovery projects for major depression. His research has also lead to the successful identification and validation of novel molecular targets for neuroendocrine diseases, one of which has entered clinical trials for Cushing's disease. Marcelo Paez-Pereda obtained his PhD in the Department of Biology of the University of Buenos Aires. He has published more than 30 scientific publications and was awarded the Ernst-und-Bertha-Scharrer Prize in 2000 and the Lucio Cherny Prize in 2002.

Dr. Michael Bös, Vice President, Research & Development

Dr. Bös has extensive experience in Drug Discovery and Development. He received his Ph.D. in medicinal chemistry from the University of Vienna. After postdoctoral studies at the ETH Zurich with Prof. D. Seebach and at Colorado State University in Fort Collins, USA, with Prof. A.I.Meyers, he joined F. Hoffmann-La Roche in Basel, Switzerland, as a medicinal chemist in 1986. At Roche, Dr. Bös was involved in a number of projects targeting diseases of the CNS such as depression, obsessive compulsive disorder and Alzheimer's disease. As an exchange scientist at Roche in Nutley, New Jersey (1989-1990), he worked on Thyrotropine Releasing Hormone where he applied computer assisted modelling for the design of new non-peptidic scaffolds. In 1999 he moved to Montreal to take up the position of director of chemistry at Boehringer Ingelheim (Canada) Ltd. During his 7 year tenure as head of a department of 58 chemists (including medicinal chemistry, analytical chemistry and structural chemistry) the first HCV NS3 protease inhibitor (BILN 2061) moved into clinical development and 6 compounds targeting HCV and HIV were granted Start of Development.